Huntington’s disease cerebrospinal fluid seeds aggregation of mutant huntingtin
Citations Over TimeTop 10% of 2015 papers
Abstract
Huntington's disease (HD), a progressive neurodegenerative disease, is caused by an expanded CAG triplet repeat producing a mutant huntingtin protein (mHTT) with a polyglutamine-repeat expansion. Onset of symptoms in mutant huntingtin gene-carrying individuals remains unpredictable. We report that synthetic polyglutamine oligomers and cerebrospinal fluid (CSF) from BACHD transgenic rats and from human HD subjects can seed mutant huntingtin aggregation in a cell model and its cell lysate. Our studies demonstrate that seeding requires the mutant huntingtin template and may reflect an underlying prion-like protein propagation mechanism. Light and cryo-electron microscopy show that synthetic seeds nucleate and enhance mutant huntingtin aggregation. This seeding assay distinguishes HD subjects from healthy and non-HD dementia controls without overlap (blinded samples). Ultimately, this seeding property in HD patient CSF may form the basis of a molecular biomarker assay to monitor HD and evaluate therapies that target mHTT.
Related Papers
- → Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington’s disease(2007)112 cited
- → Impaired mitochondrial trafficking in Huntington's disease(2009)67 cited
- → Recent Trends in Detection of Huntingtin and Preclinical Models of Huntington’s Disease(2014)5 cited
- → Inhibition of caspase-6: A potential therapy for Huntington’s disease(2008)
- Assessments of potential interactions of huntingtin-associated-protein-1 in the R6/2 mouse model of Huntington's disease(2004)